Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)

被引：0
|
作者：
Ioka, T. [1 ]
Nakamori, S. [2 ]
Sugimori, K. [3 ]
Kanai, M. [4 ]
Ikeda, M. [5 ]
Ozaka, M. [6 ]
Furukawa, M. [7 ]
Okusaka, T. [8 ]
Kawabe, K. [9 ]
Furuse, J. [10 ]
Komatsu, Y. [11 ]
Sato, A. [12 ]
Shimizu, S. [13 ]
Chugh, P. [14 ]
Tang, R. [15 ]
Ueno, M. [16 ]
机构：
[1] Osaka Int Canc Inst, Dept Canc Survey & Gastrointestinal Oncol, Osaka, Japan
[2] NHO Osaka Natl Hosp, Dept Surg, Osaka, Japan
[3] Yokohama City Univ, Med Ctr, Gastroenterol Ctr, Yokohama, Kanagawa, Japan
[4] Kyoto Univ Hosp, Dept Med Oncol, Kyoto, Japan
[5] Hosp East, Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Kashiwa, Chiba, Japan
[6] Canc Inst Hosp JFCR, Dept Gastroenterol, Tokyo, Japan
[7] NHO Kyushu Canc Ctr, Dept Gastroenterol Hepatol Pancreatol, Fukuoka, Fukuoka, Japan
[8] Natl Canc Ctr, Dept Hepatobiliary & Pancreat Oncol, Tokyo, Japan
[9] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka, Fukuoka, Japan
[10] Kyorin Univ, Fac Med, Dept Med Oncol, Mitaka, Tokyo, Japan
[11] Hokkaido Univ Hosp, Canc Ctr, Sapporo, Hokkaido, Japan
[12] Hirosaki Univ Hosp, Dept Oncol, Hirosaki, Aomori, Japan
[13] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan
[14] Servier Pharmaceut, Clin Sci, Boston, MA USA
[15] Servier Pharmaceut, Biostat & Programming, Boston, MA USA
[16] Kanagawa Canc Ctr, Hepatobiliary & Pancreat Med Oncol Div, Dept Gastroenterol, Yokohama, Kanagawa, Japan
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
132P
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Nal-IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer - Additional safety report of randomized Japanese phase 2 trial
    Ikeda, Masafumi
    Ioka, Tatsuya
    Ueno, Makoto
    Okusaka, Takuji
    Teng, Zhaoyang
    Furuya, Momoko
    Furuse, Junji
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S482
  • [12] Safety across subgroups in NAPOLI-1: a phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Chen, L. -T.
    Siveke, J.
    Wang-Gillam, A.
    Hubner, R.
    Pant, S.
    Dragovich, T.
    Chung, V.
    Chang, D.
    Ross, P.
    Cooray, P.
    Tebbutt, N.
    Franke, F.
    Belanger, B.
    Dhindsa, N.
    de Jong, F.
    Mamlouk, K.
    Von Hoff, D.
    ANNALS OF ONCOLOGY, 2016, 27 : 110 - 110
  • [13] A phase 1/2, open -label, dose -expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
    Wainberg, Z.
    Boland, P.
    Lieu, C.
    Dayyani, F.
    Macarulla, T.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Wang, T.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [14] Nal- IRI+5-FU/LV vs 5-FU/LV in metastatic pancreatic cancer: Additional safety report of randomized Japanese phase 2 trial
    Okusaka, Takuji
    Ikeda, Masafumi
    Ioka, Tatsuya
    Ueno, Makoto
    Teng, Zhaoyang
    Furuya, Momoko
    Furuse, Junji
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [15] Updated overall survival analysis of NAPOLI-1: Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy.
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Shan, Yang-Shen
    Jameson, Gayle S.
    Macarulla, Teresa
    Lee, Kyung-Hun
    Cunningham, David
    Blanc, Jean-Frederic
    Hubner, Richard
    Chiu, Chang-Fang
    Schwartsmann, Gilberto
    Siveke, Jens T.
    Braiteh, Fadi S.
    Moyo, Victor M.
    Belanger, Bruce
    Bayever, Eliel
    Von Hoff, Daniel D.
    Chen, Li-Tzong
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [16] Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Hubner, R. A.
    Chen, L-T.
    Siveke, J. T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Mamlouk, K.
    Belanger, B.
    de Jong, F.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [17] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Fotios Loupakis
    Gianluca Masi
    Lorenzo Fornaro
    Enrico Vasile
    Giacomo Allegrini
    Eloise Fontana
    Cristina Granetto
    Lisa Salvatore
    Lucia Mentuccia
    Michele Andreuccetti
    Enrico Cortesi
    Marco Merlano
    Stefano Cascinu
    Alfredo Falcone
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 559 - 566
  • [18] Phase II study of sequential cisplatin plus 5-fluorouracil/leucovorin (5-FU/LV) followed by irinotecan plus 5-FU/LV followed by docetaxel plus 5-FU/LV in patients with metastatic gastric or gastro-oesophageal junction adenocarcinoma
    Loupakis, Fotios
    Masi, Gianluca
    Fornaro, Lorenzo
    Vasile, Enrico
    Allegrini, Giacomo
    Fontana, Eloise
    Granetto, Cristina
    Salvatore, Lisa
    Mentuccia, Lucia
    Andreuccetti, Michele
    Cortesi, Enrico
    Merlano, Marco
    Cascinu, Stefano
    Falcone, Alfredo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (03) : 559 - 566
  • [19] Long-term survival in patients with pancreatic cancer (PAC) treated with liposomal irinotecan in combination with 5-fluorouracil and leucovorin (nal-IRI+5-FU/LV)
    Prager, G.
    Potthoff, K.
    Yoo, C.
    Lonardi, S.
    Hedouin-Biville, F.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S248 - S249
  • [20] Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Chen, L-T
    Von Hoff, D. D.
    Li, C-P
    Wang-Gillam, A.
    Bodoky, G.
    Dean, A.
    Shan, Y-S
    Jameson, G.
    Macarulla, T.
    Lee, K-H
    Cunningham, D.
    Blanc, J-F
    Hubner, R. A.
    Chiu, C-F
    Schwartsmann, G.
    Braiteh, F.
    Moyo, V.
    Belanger, B.
    Bayever, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 170 - 170
12345